QCM
SUPN icon

QRG Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

QRG Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$497K Sell
10,677
-71
-0.7% -$3.41K ﹤0.01% 860
2026
Q1 		$556K Buy
10,748
+1,318
+14% +$67.1K 0.01% 746
2025
Q4 		$469K Sell
9,430
-284
-3% -$13.8K 0.01% 780
2025
Q3 		$464K Sell
9,714
-9,178
-49% -$370K 0.01% 745
2025
Q2 		$595K Buy
18,892
+1,309
+7% +$42K 0.01% 765
2025
Q1 		$576K Buy
17,583
+913
+5% +$32.4K 0.01% 719
2024
Q4 		$603K Sell
16,670
-131
-0.8% -$4.61K 0.01% 723
2024
Q3 		$524K Buy
16,801
+986
+6% +$30.8K 0.01% 764
2024
Q2 		$423K Sell
15,815
-792
-5% -$23K 0.01% 781
2024
Q1 		$566K Buy
16,607
+1,118
+7% +$33.3K 0.01% 709
2023
Q4 		$448K Buy
15,489
+398
+3% +$10.6K 0.01% 759
2023
Q3 		$416K Buy
+15,091
New +$459K 0.01% 717

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

QRG Capital Management's SUPN Position: Q2 2026 in Review

QRG Capital Management reduced its Supernus Pharmaceuticals (SUPN) stake by 0.66% in Q2 2026, selling an estimated $3.41K and leaving 10,677 shares worth $497K. The position accounts for ﹤0.01% of the portfolio, ranked #860.

QRG Capital Management first reported a position in SUPN in Q3 2023 and has held it in 12 quarters since. The position peaked at $603K in Q4 2024. 332 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • QRG Capital Management held 10,677 shares of Supernus Pharmaceuticals worth $497K as of Q2 2026.
  • QRG Capital Management sold 71 Supernus Pharmaceuticals shares in Q2 2026, an estimated $3.41K.
  • Supernus Pharmaceuticals made up ﹤0.01% of QRG Capital Management's portfolio in Q2 2026, its #860 holding.
  • QRG Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • QRG Capital Management's Supernus Pharmaceuticals position peaked at $603K in Q4 2024.
  • 332 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on QRG Capital Management's 13F filing for Q2 2026, filed 14 Jul 2026.